{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T19:42:04Z","timestamp":1787427724109,"version":"build-2736575974"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS118"],"award-info":[{"award-number":["YDZJ202201ZYTS118"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","award":["2023SCZ09"],"award-info":[{"award-number":["2023SCZ09"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013061","name":"Jilin Provincial Scientific and Technological Development Program","doi-asserted-by":"publisher","award":["20240601013RC"],"award-info":[{"award-number":["20240601013RC"]}],"id":[{"id":"10.13039\/501100013061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92974-x","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T16:17:58Z","timestamp":1742401078000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development and validation of predictive models for distant metastasis and prognosis of gastroenteropancreatic neuroendocrine neoplasms"],"prefix":"10.1038","volume":"15","author":[{"given":"Xuan-Peng","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luan-Biao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Peng","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo-Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"issue":"10","key":"92974_CR1","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.3748\/wjg.v28.i10.1009","volume":"28","author":"JM Fang","year":"2022","unstructured":"Fang, J. M., Li, J. & Shi, J. An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. World J. Gastroenterol. 28(10), 1009\u20131023 (2022).","journal-title":"World J. Gastroenterol."},{"key":"92974_CR2","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.35463","volume":"13","author":"AJH Sedlack","year":"2024","unstructured":"Sedlack, A. J. H. et al. Update in the management of gastroenteropancreatic neuroendocrine tumors. Cancer 13, 3090 (2024).","journal-title":"Cancer"},{"issue":"10","key":"92974_CR3","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari, A. et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 3(10), 1335\u20131342 (2017).","journal-title":"JAMA Oncol."},{"issue":"6","key":"92974_CR4","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3322\/caac.21493","volume":"68","author":"M Cives","year":"2018","unstructured":"Cives, M. & Strosberg, J. R. Gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 68(6), 471\u2013487 (2018).","journal-title":"CA Cancer J. Clin."},{"issue":"9","key":"92974_CR5","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.24750","volume":"4","author":"Z Xu","year":"2021","unstructured":"Xu, Z. et al. Epidemiologic trends of and factors associated with overall survival for patients with gastroenteropancreatic neuroendocrine tumors in the United States. JAMA Netw. Open 4(9), e2124750 (2021).","journal-title":"JAMA Netw. Open"},{"issue":"2","key":"92974_CR6","first-page":"158","volume":"49","author":"R Modica","year":"2024","unstructured":"Modica, R. et al. Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms. Minerva Endocrinol. (Torino) 49(2), 158\u2013174 (2024).","journal-title":"Minerva Endocrinol. (Torino)"},{"issue":"5","key":"92974_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.2217\/fon-2020-0543","volume":"17","author":"L Lu","year":"2021","unstructured":"Lu, L. et al. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: An updated population-based study. Future Oncol. 17(5), 549\u2013563 (2021).","journal-title":"Future Oncol."},{"key":"92974_CR8","doi-asserted-by":"publisher","first-page":"1264952","DOI":"10.3389\/fendo.2024.1264952","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X. et al. Risk factors, prognostic factors, and nomograms for distant metastases in patients with gastroenteropancreatic neuroendocrine tumors: A population-based study. Front. Endocrinol. (Lausanne) 15, 1264952 (2024).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"1","key":"92974_CR9","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","volume":"33","author":"G Rindi","year":"2022","unstructured":"Rindi, G. et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr. Pathol. 33(1), 115\u2013154 (2022).","journal-title":"Endocr. Pathol."},{"issue":"2","key":"92974_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12022-024-09807-2","volume":"35","author":"S Uccella","year":"2024","unstructured":"Uccella, S. Molecular classification of gastrointestinal and pancreatic neuroendocrine neoplasms: Are we ready for that?. Endocr. Pathol. 35(2), 91\u2013106 (2024).","journal-title":"Endocr. Pathol."},{"key":"92974_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.semcancer.2021.04.011","volume":"79","author":"G Effraimidis","year":"2022","unstructured":"Effraimidis, G. et al. Multiple endocrine neoplasia type 1 (MEN-1) and neuroendocrine neoplasms (NENs). Semin. Cancer Biol. 79, 141\u2013162 (2022).","journal-title":"Semin. Cancer Biol."},{"issue":"6","key":"92974_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s11864-022-00969-x","volume":"23","author":"P Holmager","year":"2022","unstructured":"Holmager, P. et al. Surgery in patients with gastro-entero-pancreatic neuroendocrine carcinomas, neuroendocrine tumors G3 and high grade mixed neuroendocrine-non-neuroendocrine neoplasms. Curr. Treat. Options Oncol. 23(6), 806\u2013817 (2022).","journal-title":"Curr. Treat. Options Oncol."},{"issue":"8","key":"92974_CR13","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1245\/s10434-016-5734-x","volume":"24","author":"A Madani","year":"2017","unstructured":"Madani, A. et al. Peritoneal metastases from gastroenteropancreatic neuroendocrine tumors: Incidence, risk factors and prognosis. Ann. Surg. Oncol. 24(8), 2199\u20132205 (2017).","journal-title":"Ann. Surg. Oncol."},{"issue":"18","key":"92974_CR14","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao, J. C. et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol. 26(18), 3063\u20133072 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"92974_CR15","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1007\/s00330-015-3941-7","volume":"26","author":"JH Kim","year":"2016","unstructured":"Kim, J. H. et al. Pancreatic neuroendocrine tumour (PNET): Staging accuracy of MDCT and its diagnostic performance for the differentiation of PNET with uncommon CT findings from pancreatic adenocarcinoma. Eur. Radiol. 26(5), 1338\u20131347 (2016).","journal-title":"Eur. Radiol."},{"issue":"7","key":"92974_CR16","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel, M. et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(7), 844\u2013860 (2020).","journal-title":"Ann. Oncol."},{"issue":"6","key":"92974_CR17","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13311","volume":"35","author":"L de Mestier","year":"2023","unstructured":"de Mestier, L. et al. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST. J. Neuroendocrinol. 35(6), e13311 (2023).","journal-title":"J. Neuroendocrinol."},{"issue":"2","key":"92974_CR18","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/jcm12020717","volume":"12","author":"A Zappi","year":"2023","unstructured":"Zappi, A. et al. Chemotherapy in well differentiated neuroendocrine tumors (NET) G1, G2, and G3: A narrative review. J. Clin. Med. 12(2), 717 (2023).","journal-title":"J. Clin. Med."},{"issue":"5","key":"92974_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2023.101794","volume":"37","author":"N Fazio","year":"2023","unstructured":"Fazio, N. & La Salvia, A. Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: Where are we in 2023?. Best Pract. Res. Clin. Endocrinol. Metab. 37(5), 101794 (2023).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"92974_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1196\/annals.1294.002","volume":"1014","author":"G Kl\u00f6ppel","year":"2004","unstructured":"Kl\u00f6ppel, G., Perren, A. & Heitz, P. U. The gastroenteropancreatic neuroendocrine cell system and its tumors: The WHO classification. Ann. N. Y. Acad. Sci. 1014, 13\u201327 (2004).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"92974_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.6004\/jnccn.2015.0011","volume":"13","author":"MH Kulke","year":"2015","unstructured":"Kulke, M. H. et al. Neuroendocrine tumors, version 1.2015. J. Natl. Compr. Cancer Netw. 13(1), 78\u2013108 (2015).","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"92974_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102299","volume":"101","author":"R Broadbent","year":"2021","unstructured":"Broadbent, R. et al. Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treat. Rev. 101, 102299 (2021).","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"92974_CR23","first-page":"426","volume":"42","author":"Y Li","year":"2020","unstructured":"Li, Y. et al. Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms. Zhonghua Zhong Liu Za Zhi 42(5), 426\u2013431 (2020).","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"11","key":"92974_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s00535-021-01827-7","volume":"56","author":"T Ito","year":"2021","unstructured":"Ito, T. et al. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: Diagnosis, treatment, and follow-up: A synopsis. J. Gastroenterol. 56(11), 1033\u20131044 (2021).","journal-title":"J. Gastroenterol."},{"issue":"1","key":"92974_CR25","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(07)70410-2","volume":"9","author":"IM Modlin","year":"2008","unstructured":"Modlin, I. M. et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9(1), 61\u201372 (2008).","journal-title":"Lancet Oncol."},{"key":"92974_CR26","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1472-6823-14-54","volume":"14","author":"X Zhang","year":"2014","unstructured":"Zhang, X. et al. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: A retrospective study. BMC Endocr. Disord. 14, 54 (2014).","journal-title":"BMC Endocr. Disord."},{"issue":"3","key":"92974_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.path.2020.04.002","volume":"13","author":"RS Gonzalez","year":"2020","unstructured":"Gonzalez, R. S. Diagnosis and management of gastrointestinal neuroendocrine neoplasms. Surg. Pathol. Clin. 13(3), 377\u2013397 (2020).","journal-title":"Surg. Pathol. Clin."},{"issue":"1","key":"92974_CR28","first-page":"29","volume":"26","author":"M D\u00edez","year":"2013","unstructured":"D\u00edez, M., Teul\u00e9, A. & Salazar, R. Gastroenteropancreatic neuroendocrine tumors: Diagnosis and treatment. Ann. Gastroenterol. 26(1), 29\u201336 (2013).","journal-title":"Ann. Gastroenterol."},{"issue":"1","key":"92974_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MPA.0000000000001454","volume":"49","author":"JR Howe","year":"2020","unstructured":"Howe, J. R. et al. The North American neuroendocrine tumor society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 49(1), 1\u201333 (2020).","journal-title":"Pancreas"},{"issue":"1","key":"92974_CR30","first-page":"35","volume":"11","author":"XB Zhang","year":"2024","unstructured":"Zhang, X. B. et al. Gastroenteropancreatic neuroendocrine neoplasms: Current development, challenges, and clinical perspectives. Mil. Med. Res. 11(1), 35 (2024).","journal-title":"Mil. Med. Res."},{"key":"92974_CR31","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ejca.2021.06.056","volume":"157","author":"M Pavel","year":"2021","unstructured":"Pavel, M. et al. Efficacy and safety of high-dose lanreotide autogel in patients with progressive pancreatic or midgut neuroendocrine tumours: CLARINET FORTE phase 2 study results. Eur. J. Cancer 157, 403\u2013414 (2021).","journal-title":"Eur. J. Cancer"},{"key":"92974_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102560","volume":"117","author":"A La Salvia","year":"2023","unstructured":"La Salvia, A. et al. Targeting neuroendocrine tumors with octreotide and lanreotide: Key points for clinical practice from NET specialists. Cancer Treat. Rev. 117, 102560 (2023).","journal-title":"Cancer Treat. Rev."},{"issue":"8","key":"92974_CR33","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1634\/theoncologist.2018-0519","volume":"24","author":"MH Kulke","year":"2019","unstructured":"Kulke, M. H. et al. Real-world treatment patterns and clinical outcomes in advanced gastrointestinal neuroendocrine tumors (GI NET): A multicenter retrospective chart review study. Oncologist 24(8), 1056\u20131065 (2019).","journal-title":"Oncologist"},{"issue":"7","key":"92974_CR34","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1200\/JCO.22.01013","volume":"41","author":"PL Kunz","year":"2023","unstructured":"Kunz, P. L. et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211). J. Clin. Oncol. 41(7), 1359\u20131369 (2023).","journal-title":"J. Clin. Oncol."},{"key":"92974_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.861434","volume":"13","author":"G Puliani","year":"2022","unstructured":"Puliani, G. et al. New Insights in PRRT: Lessons from 2021. Front. Endocrinol. (Lausanne) 13, 861434 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"8","key":"92974_CR36","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.1007\/s00432-022-04314-5","volume":"149","author":"V Rosery","year":"2023","unstructured":"Rosery, V. et al. Identification of a new prognostic score for patients with high-grade metastatic GEP-NEN treated with palliative chemotherapy. J. Cancer Res. Clin. Oncol. 149(8), 4315\u20134325 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"1","key":"92974_CR37","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/annonc\/mds276","volume":"24","author":"H Sorbye","year":"2013","unstructured":"Sorbye, H. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann. Oncol. 24(1), 152\u2013160 (2013).","journal-title":"Ann. Oncol."},{"issue":"12","key":"92974_CR38","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg, J. R. et al. (177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): Final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 22(12), 1752\u20131763 (2021).","journal-title":"Lancet Oncol."},{"issue":"2","key":"92974_CR39","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel, M. et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2), 172\u2013185 (2016).","journal-title":"Neuroendocrinology"},{"issue":"6","key":"92974_CR40","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364(6), 501\u2013513 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"92974_CR41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","volume":"3","author":"Z Feng","year":"2022","unstructured":"Feng, Z. et al. Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues. Nat. Cancer 3(5), 581\u2013594 (2022).","journal-title":"Nat. Cancer"},{"issue":"26","key":"92974_CR42","doi-asserted-by":"publisher","first-page":"4174","DOI":"10.3748\/wjg.v29.i26.4174","volume":"29","author":"WX Pan","year":"2023","unstructured":"Pan, W. X. et al. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system. World J. Gastroenterol. 29(26), 4174\u20134185 (2023).","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"92974_CR43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1159\/000518106","volume":"113","author":"IR Popa Ilie","year":"2023","unstructured":"Popa Ilie, I. R. & Georgescu, C. E. Immunotherapy in gastroenteropancreatic neuroendocrine neoplasia. Neuroendocrinology 113(2), 262\u2013278 (2023).","journal-title":"Neuroendocrinology"},{"key":"92974_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111726","volume":"555","author":"R Uhlig","year":"2022","unstructured":"Uhlig, R. et al. Synaptophysin and chromogranin A expression analysis in human tumors. Mol. Cell Endocrinol. 555, 111726 (2022).","journal-title":"Mol. Cell Endocrinol."},{"key":"92974_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.808448","volume":"12","author":"X Lou","year":"2022","unstructured":"Lou, X. et al. The interplay of four main pathways recomposes immune landscape in primary and metastatic gastroenteropancreatic neuroendocrine tumors. Front. Oncol. 12, 808448 (2022).","journal-title":"Front. Oncol."},{"issue":"2","key":"92974_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1158\/1078-0432.CCR-21-2291","volume":"28","author":"G Boons","year":"2022","unstructured":"Boons, G. et al. Longitudinal copy-number alteration analysis in plasma cell-free DNA of neuroendocrine neoplasms is a novel specific biomarker for diagnosis, prognosis, and follow-up. Clin. Cancer Res. 28(2), 338\u2013349 (2022).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"92974_CR47","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12885-023-10722-8","volume":"23","author":"B Almobarak","year":"2023","unstructured":"Almobarak, B. et al. Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype. BMC Cancer 23(1), 267 (2023).","journal-title":"BMC Cancer"},{"issue":"4","key":"92974_CR48","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3322\/caac.21840","volume":"74","author":"A Chauhan","year":"2024","unstructured":"Chauhan, A. et al. Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J. Clin. 74(4), 359\u2013367 (2024).","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"92974_CR49","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1200\/JCO.2007.12.9791","volume":"26","author":"A Iasonos","year":"2008","unstructured":"Iasonos, A. et al. How to build and interpret a nomogram for cancer prognosis. J. Clin. Oncol. 26(8), 1364\u20131370 (2008).","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"92974_CR50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdz001","volume":"30","author":"D Dong","year":"2019","unstructured":"Dong, D. et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer. Ann. Oncol. 30(3), 431\u2013438 (2019).","journal-title":"Ann. Oncol."},{"key":"92974_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.771226","volume":"12","author":"Y Min","year":"2021","unstructured":"Min, Y. et al. Risk factors, prognostic factors, and nomogram for distant metastasis in breast cancer patients without lymph node metastasis. Front. Endocrinol. (Lausanne) 12, 771226 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"9","key":"92974_CR52","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1016\/j.jtho.2018.05.037","volume":"13","author":"S Wang","year":"2018","unstructured":"Wang, S. et al. Development and validation of a nomogram prognostic model for SCLC patients. J. Thorac. Oncol. 13(9), 1338\u20131348 (2018).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"92974_CR53","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7150\/ijbs.28720","volume":"15","author":"X Wang","year":"2019","unstructured":"Wang, X. et al. Development and validation of a prognostic nomogram in AFP-negative hepatocellular carcinoma. Int. J. Biol. Sci. 15(1), 221\u2013228 (2019).","journal-title":"Int. J. Biol. Sci."},{"key":"92974_CR54","doi-asserted-by":"crossref","unstructured":"La Salvia, A., et al. Gender impact on pancreatic neuroendocrine neoplasm (PanNEN) prognosis according to survival nomograms. Endocrine (2024).","DOI":"10.1007\/s12020-024-04129-z"},{"key":"92974_CR55","doi-asserted-by":"publisher","first-page":"1061187","DOI":"10.3389\/fendo.2023.1061187","volume":"14","author":"F Zhao","year":"2023","unstructured":"Zhao, F. et al. Epidemiological trends and novel prognostic evaluation approaches of patients with stage II-IV colorectal neuroendocrine neoplasms: A population-based study with external validation. Front. Endocrinol. (Lausanne) 14, 1061187 (2023).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"12","key":"92974_CR56","doi-asserted-by":"publisher","first-page":"10925","DOI":"10.1007\/s00432-023-04979-6","volume":"149","author":"E Kidess","year":"2023","unstructured":"Kidess, E. et al. Osteopontin is a prognostic circulating biomarker in patients with neuroendocrine neoplasms. J. Cancer Res. Clin. Oncol. 149(12), 10925\u201310933 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"92974_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104460","volume":"203","author":"CO Hoff","year":"2024","unstructured":"Hoff, C. O. et al. A neuroendocrine biomarker revolution from monoanalyte to multianalyte biomarkers in non-functioning gastro-entero-pancreatic neuroendocrine neoplasms. Crit. Rev. Oncol. Hematol. 203, 104460 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"3","key":"92974_CR58","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s12020-021-02959-9","volume":"75","author":"KI Alexandraki","year":"2022","unstructured":"Alexandraki, K. I., Zatelli, M. C. & Grossman, A. B. \u201cThe past is a different country, they do things differently there\u201d: Using the SEER data-base to assess prognosis in neuroendocrine tumours. Endocrine 75(3), 725\u2013727 (2022).","journal-title":"Endocrine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92974-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92974-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92974-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T23:19:40Z","timestamp":1742426380000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92974-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92974"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92974-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"assertion":[{"value":"16 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All experiments were performed in accordance with relevant guidelines and regulations. All participants provided written informed consent to be involved in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"9510"}}